Hartford Hospital Debuts MacTel Treatment

0:00Hartford Hospital just made history as the first in the region to implant a groundbreaking retinotherapy for macular, telangiectasia, tytoon, or mactel, a rare eye disease with no prior approved treatments. Dr. Scott Walter, their vice chief of ophthalmology, led the team in placing the first two of these Enselto implants right there in Connecticut. This tiny device goes surgically inside the eye, packed with living, genetically engineered cells that keep pumping out a protective protein to shield. Retinal cells and slow down vision loss. It's fresh off FDA approval, putting Hartford among the earliest spots in the country offering it. Mactel hits the macula, that central part of the red in the handling sharp, detailed site, causing blurred or warped central vision over time, making, reading or spotting faces tough. Patients finally have a real shot at holding onto their vision longer. The hospital spent nearly nine months prepping across departments like pharmacy, surgery, and anesthesia to handle these live cell implants perfectly.

1:03Their ocular oncology program draws tough cases from all over, showing why they're ahead on this. With teams now rolling out more procedures, this steps of hope for folks with rare eye issues, proving top care can hit close to home and change. Lives. From your city, powered by AI, this is Hartford News Today. I'm Corey with The Story.